• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Centessa Pharmaceuticals plc (CNTA) Stock Price, News & Analysis

Centessa Pharmaceuticals plc (CNTA) Stock Price, News & Analysis

Currency in USD Disclaimer

$18.18

$1.44

(8.61%)

Day's range
$15.43
Day's range
$18.29
50-day range
$14.48
Day's range
$18.74
  • Country: GB
  • ISIN: US1523091007
52 wk range
$5.58
Day's range
$18.74
  • CEO: Dr. Saurabh Saha M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.22
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (CNTA)
  • Company Centessa Pharmaceuticals plc
  • Price $18.18
  • Changes Percentage (8.61%)
  • Change $1.44
  • Day Low $15.43
  • Day High $18.29
  • Year High $18.74

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $23.00
  • High Stock Price Target $28.00
  • Low Stock Price Target $19.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.42
  • Trailing P/E Ratio -6.2
  • Forward P/E Ratio -6.2
  • P/E Growth -6.2
  • Net Income $-151,085,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Centessa Pharmaceuticals plc Frequently Asked Questions

  • What were the earnings of CNTA in the last quarter?

    In the last quarter Centessa Pharmaceuticals plc earnings were on Tuesday, November, 12th. The Centessa Pharmaceuticals plc maker reported -$0.37 EPS for the quarter, beating analysts' consensus estimates of -$0.42 by $0.05.

  • What is the Centessa Pharmaceuticals plc stock price today?

    Today's price of Centessa Pharmaceuticals plc is $18.18 — it has increased by +8.61% in the past 24 hours. Watch Centessa Pharmaceuticals plc stock price performance more closely on the chart.

  • Does Centessa Pharmaceuticals plc release reports?

    Yes, you can track Centessa Pharmaceuticals plc's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Centessa Pharmaceuticals plc stock forecast?

    Watch the Centessa Pharmaceuticals plc chart and read a more detailed Centessa Pharmaceuticals plc stock forecast to see what analysts suggest you do with its shares.

  • What is Centessa Pharmaceuticals plc stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Centessa Pharmaceuticals plc stock ticker.

  • How to buy Centessa Pharmaceuticals plc stocks?

    Like other stocks, CNTA shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Centessa Pharmaceuticals plc's EBITDA?

    Centessa Pharmaceuticals plc measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Centessa Pharmaceuticals plc’s financial statements.

  • What is the Centessa Pharmaceuticals plc's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -22.0465489567, which equates to approximately -2,204.65%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Centessa Pharmaceuticals plc stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Centessa Pharmaceuticals plc's financials relevant news, and technical analysis. Centessa Pharmaceuticals plc's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Centessa Pharmaceuticals plc stock currently indicates a “sell” signal. For more insights, review Centessa Pharmaceuticals plc’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.